SCHEMBL4820745

SCHEMBL4820745

[CH2]/C=C/c1ccc(Oc2ccc(C)nn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 4/20 0.39
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GAA P10253 1/20 0.35
BCAT2 O15382 1/20 0.34
P2RX3 P56373 3/20 0.34
APLNR P35414 1/20 0.33
RELA Q04206 1/20 0.33
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TSHR P16473 2/20 0.33
CYP3A4 P08684 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134383 0.77 MEN1 (0.83) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL753246 0.74 MEN1 (0.59) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL4797272 0.74 MEN1 (0.59) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL851116 0.74 MEN1 (0.59) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL4797268 0.74 MEN1 (0.59) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL753331 0.73 BCAT2 (0.60) MEN1KMT2ANPC1RAB9ABCAT2
SCHEMBL20176871 0.72 MEN1 (0.55) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL6852317 0.71 APLNR (0.36) KDM4ENPC1RAB9AAPLNRRELA
SCHEMBL8736571 0.71 MEN1 (0.55) MEN1KMT2ANPC1RAB9ABCAT2
SCHEMBL4050755 0.70 MEN1 (0.53) MEN1KMT2ANPC1RAB9ABCAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 MEN1 873/4885KMT2A 1273/4885KDM4E 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.